Exhibit 10.13

SERVICE AGREEMENT

FOR A CLINICAL STUDY CONDUCT

concluded on 16 December 2013 (“Effective Date”) in Warsaw by and between:

KCR S.A. (Polish joint-stock company) with its registered office in Warsaw at 6 Postępu Str., 02-676 Warsaw, Poland, entered in the register of entrepreneurs kept by the District Court for the Capital City of Warsaw in Warsaw, 13th Commercial Division of the National Court Register, under number 0000289542, tax identification number NIP: 521-31-69-665, share capital (covered in total): PLN 700,000.00, hereinafter referred to as “CRO”, represented by Mr. Mike Jagielski – President of the Management Board and Ms. Anna Baran – Vice President of the Management Board,

and

Vascular Biogenics Ltd., its principal place of business at 6 Jonathan Netanyahu Street, Or Yehuda, Israel 60376 hereinafter referred to as “Sponsor”, represented by Prof. Dror Harats—Chief Executive Officer,

hereinafter jointly referred to as „the Parties” and individually as a “Party”.

Whereas:

a) Sponsor intends to conduct a clinical study of the investigational medicinal product VB-201 [„Investigational Medicinal Product”] entitled “A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis” [„Study”] according to the protocol number VB-201-079 [“Protocol”] on the territory of Poland,

b) Legal Representative of the Sponsor is SCIderm GmbH, a company organized and existing under the laws of Federal Republic of Germany, entered in the Trade Register maintained by the District Court in Hamburg, under the number HRB 93824 with its registered office at Drehbahn 1-3, 20354 Hamburg, Germany,

c) Sponsor wishes to engage CRO to provide services connected with the conduct of the Study as defined herein,

VBL Confidential Information	Page 1 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

d) fulfillment of CRO’s obligations resulting from this agreement is included in the scope of CRO’s business activity and CRO has an experience in providing services of similar nature as described herein, including the fact that CRO employs qualified employees in order to perform such obligations.

Now then, the Parties agree to conclude the agreement as follows [„Agreement”]:

§ 1. Subject of the Agreement

1. Sponsor hereby entrusts CRO with performance of activities connected with the conduct of the Study as defined in Attachment No. 1 hereto (Scope of Services), hereinafter referred to as „Services”, and CRO hereby accepts such entrusted responsibilities.

2. Services shall be performed within the timelines indicated in Attachment No. 2. Parties declare that these timelines shall be deemed as a forecast only and may be changed due to reasons which are not attributable to the CRO. In case of necessity to provide Services within different timelines than those anticipated in Attachment No. 2 for reasons not attributable to CRO, Sponsor waives its right to bring any claims against CRO for an untimely provision of Services.

§ 2. Manner of Providing Services

1. CRO shall perform its responsibilities, in the scope indicated in the Agreement, with due diligence and in compliance with laws and regulations in force applicable in the countries where the Services will be performed, guidelines of Good Manufacturing Practice, Good Laboratory Practice, Good Clinical Practice, ICH GCP in a version applicable during the term of the Study conduct, in compliance with the Agreement and a valid version of the Protocol, constituting Attachment No. 3 to the Agreement, CRO’s SOPs listed in Attachment No. 4 and any written instructions of the Sponsor.

2. The CRO represents and warrants that it has obtained, and will maintain throughout the term of this Agreement, all governmental or regulatory approvals, licenses, registrations and insurances that may be required to complete the Study, and that it has full right, power and authority to perform its obligations hereunder and to grant the rights set forth herein. During the term of this Agreement the CRO shall not conduct any other trial which, at the CRO’s

VBL Confidential Information	Page 2 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

discretion, would adversely affect the ability of the CRO to perform their obligations under this Agreement.

3. In order to perform Services, CRO undertakes an obligation to appoint from among its employees only persons with appropriate knowledge, experience and qualifications necessary to perform Services, and who have bound by confidentiality undertakings according to this Agreement.

4. The CRO certifies that it has not and will not use in any capacity in connection with this Agreement the services of any individual, corporation, partnership, or association which has been debarred, excluded, or disqualified from participation in clinical investigations under any applicable laws, regulations, or guidance. In the event that the CRO receives notice of the debarment or threatened debarment, exclusion or disqualification or threatened disqualification, of any individual, corporation, partnership or association providing services to the CRO, which relate to its activities under this Agreement, the CRO shall notify the Sponsor immediately.

5. If the Sponsor raises any objections regarding provision of Services by a particular CRO employee, the Sponsor shall notify CRO of that fact in writing and may request replacement of such employee solely due to material and reasonable objections against his/her work or behavior. CRO shall appoint a new employee with appropriate qualifications and experience in the shortest possible time.

6. Sponsor shall have the right to reject any Services that it deems in nonconformance with the Protocol or the Agreement. Sponsor shall provide CRO with written notification of the deficiency or non-conformance and, within thirty (30) days of receipt of such written notification, CRO shall correct the deficiency or non-conformance at CRO’s expense.

7. During the term of the Agreement and subject to the prior approval of the Sponsor (e-mail form is acceptable), CRO may entrust a third party, such as sites, investigators, and other relevant sub-contractors (“Sub-contractors”) with performance of all or some of the Services while observing due diligence in this choice, provided that such Sub-contractors are made aware of and acknowledge the obligations applicable to such Sub-contractors according to this Agreement including without limitation confidentiality, Intellectual property rights and publications. The CRO shall ensure, and shall at all times remain jointly and severally responsible and liable, for the compliance of such Sub-contractors with the terms of this Agreement. For the avoidance of doubt, the Parties agree that this section shall not release

VBL Confidential Information	Page 3 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

the Sponsor or the investigators from liability for the Study conduct according to provisions of law in force.

8. CRO acknowledge that the Sponsor may entrust third parties with performance of services, which are related to the Study but are not included in the Services, which shall be provided by the CRO. A list of such third parties attached hereto as Attachment 5 or as shall be amended by the Sponsor from time to time. CRO warrants that (i) it will fully cooperate with such third parties according to the Sponsor’s written instructions as necessary to the conduct of the Study and (ii) it will be obligated by the relevant written instructions imposed by such third parties as shall be presented to the CRO by such third party or the Sponsor.

9. CRO warrants that the assumptions underlying each Attachment and/or timeline have been arrived at in good faith by CRO, based upon its experience and professional judgment. In the event the CRO or Sponsor requests to amend the Services, timelines or budget for a Study, the Parties agree to negotiate in good faith a written change order signed by the duly authorized representatives of the Parties.

10. Both Sponsor and CRO shall carry, at its sole expense, with financially sound and reputable insurers, an insurance coverage with respect to the conduct of its business.

§ 3. Sponsor’s responsibilities

Sponsor undertakes an obligation in particular to:

a) provide CRO with all information in its possession about the Investigational Medicinal Product necessary for the conduct of the Study,

b) keep CRO informed on an ongoing basis about any new findings concerning safety of the Investigational Medicinal Product,

c) supply CRO with the Investigational Medicinal Product manufactured in compliance with Good Manufacturing Practice, adequately packed and labeled,

d) supply CRO with documentation necessary for conduct of the Study, including the valid version of the Protocol, Investigator’s Brochure and the Case Report Forms (CRF),

e) conclude insurance agreement on third party liability of the Sponsor and investigators for damages related to the conduct of the Study, in compliance with laws in force and provide CRO with a valid copy of the insurance policy confirming conclusion of such agreement,

f) notify CRO immediately of any suspension of the Study or withdrawal of the approval for the conduct of the Study,

VBL Confidential Information	Page 4 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

g) perform other responsibilities not assigned to the CRO and necessary for the conduct of the Study.

§ 4. Audits and inspections

1. On Sponsor’s reasonable request, CRO shall, at any time, provide the Sponsor with information on the status of the Services performed. In particular, the Sponsor may request CRO to prepare an activity report on the Services performed by CRO.

2. During the term of the Agreement, CRO undertakes an obligation to allow the Sponsor and any competent authorities and national, foreign and international bodies or organizations responsible for registration of medicinal products and supervision, audit or inspection of clinical studies to conduct an audit, control or inspection of the Study as well as to access the records related to the Study conduct, and to monitor and audit the activities of the investigators and members of the study teams during the Study (including inspection and audit of the facilities and procedures used in the Study by the investigators and the study teams, as well as the equipment, data registration method and storing the records), and to enable both Sponsor and any national, foreign and international bodies or organizations responsible for registration of medicinal products and supervision or inspection of clinical studies to obtain any and all information on the conduct of the Study.

3. CRO shall notify Sponsor if any competent authorities and national, foreign and international bodies or organizations responsible for registration of medicinal products and supervision, audit or inspection of clinical studies inform CRO about any scheduled, or begin an unscheduled inspection of any study site, CRO or bioethics committee. CRO shall immediately provide the Sponsor with any correspondence and/or communication related to a notification, conduct and results of an audit or inspection and shall inform the Sponsor of the measures to be taken following finding and recommendations of such inspection and audits and their results.

4. Sponsor agrees to cover the costs of CRO’s employees involvement in an audit, control or inspection based on real time spent on such activities according to the rates described in Attachment No. 6.

VBL Confidential Information	Page 5 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

§ 5. Remuneration

1. For execution of all obligations resulting from the Agreement by CRO, Sponsor undertakes an obligation to pay remuneration as well as reimburse costs and expenses as defined in net amounts in Attachment No. 6. Due VAT shall be added to the above fee.

2. The Sponsor is obliged to make payments within 30 days from the receipt of a VAT invoice from CRO and provided that the CRO has provided upon the execution of this Agreement a Certificate of Residency from its Tax Authorities. If it is necessary to convert one currency into another, it shall be calculated by CRO on the basis of a current foreign exchange selling rate of the Polish National Bank announced on the date of the VAT invoice issuance.

3. The remuneration shall be calculated and paid on a monthly basis for the time committed to or a type of Services provided in a given month within 30 days from the delivery of the invoice issued by CRO to the Sponsor. CRO shall be entitled to issue and deliver a VAT invoice beginning with the last day of a given month for the amount covering time or type of Services performed in such month.

4. On Sponsor’s request, CRO shall submit a list of Services performed in a given month, including a timesheet of persons providing Services with a detailed description of activities performed.

5. The Sponsor shall reimburse CRO:

a) for any costs incurred by CRO in connection with conclusion of the Agreement and providing the Services hereunder—so called “pass through costs”, including in particular costs of telephone connections, faxes, internet, courier and mail services, accommodation and travel expenses of persons appointed to perform Services, which will be incurred in connection with the execution of the Agreement. These expenses will be invoiced on a monthly basis and presented to the Sponsor with a detailed list.

b) for any costs related to use of CRO company cars for business travels to and from study sites indicated by the Sponsor,

c) for any other costs necessary for the proper conduct of the Study provided that such expenses have been pre-approved by the Sponsor.

6. Specification of expected costs and expenses (so called „pass through costs”) is included in Attachment No. 6 hereto. In case if costs, expenses or a scope of Services connected with the conduct of the Study appear to be higher than those anticipated on the Agreement date, the Sponsor undertakes an obligation to cover these costs and reimburse CRO for expenses incurred

VBL Confidential Information	Page 6 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

in relation to the execution of the Agreement provided that such expenses have been pre-approved by the Sponsor.

7. When CRO is in charge of investigators, sites, Study subject or IRB/EC fees or expenses payment or reimbursement, estimated or known amounts for such payments/reimbursements will be invoiced to the Sponsor, before paying such fees or expenses. The CRO has no obligation to advance funds and make these payments unless and until the funds are received from the Sponsor. If Sponsor does not provide funds in time to enable CRO to make timely payments, Sponsor agrees to be liable for and to reimburse CRO for any interest and other charges, costs, fees and expenses incurred by CRO because of such late payment. Any excess funds paid to CRO for such fees and expenses shall be refunded to Sponsor at the end of the Study or sooner, upon Sponsor’s request.

8. Sponsor is obliged to reimburse CRO for the costs and expenses incurred by CRO in relation to the execution of the Agreement within 30 days from the receipt of relevant documentary evidence supporting such costs and expenses from CRO.

9. Payment of the remuneration and reimbursement of costs incurred by CRO shall be made by a transfer to CRO bank account indicated on the invoice.

10. CRO rates included in the budget in Attachment 6 shall automatically increase each calendar year beginning from January 1, 2015 for the next 12 month period, according to year inflation rate published by Eurostat, the Statistical Office of the European Communities. The Parties agree that increase of rates shall be effective from the beginning of calendar year regardless of the date of publishing year inflation rate by Eurostat.

§ 6. Confidentiality

1. The CRO shall keep confidential any and all information and data concerning Sponsor`s business or its activities (including reports and information as well as all clinical data about the Study or its progress produced by the CRO or the sites within the framework of this Agreement), or information obtained that may come to the knowledge of the CRO, its personnel or appointed representatives during or in connection with the execution of this Agreement including without limitation third party confidential information received by the Sponsor (“Sponsor’s Confidential Information”). For the avoidance of any doubt, the Protocol, the Investigational Medicinal Product, the Study results, and the Inventions (as defined below) shall be considered the Sponsor’s Confidential Information.

VBL Confidential Information	Page 7 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

2. Sponsor shall keep confidential any and all information and data concerning the CRO`s business or its activities (including information produced by Sponsor within the framework of this Agreement) or information obtained that may come to the knowledge of Sponsor, its personnel or appointed representatives during or in connection with the execution of this Agreement, and is not considered Sponsor’s Confidential Information.

3. Parties undertake an obligation to keep strictly confidential any confidential information or data which came into possession of the other Party in any manner, were delivered or otherwise disclosed to the other Party in connection with the Agreement. Parties may use and make the above mentioned information available solely for the purpose of the execution of the Agreement.

4. The above provision does not apply to information which the receiving Party can demonstrate that:

a) is known to the receiving Party at the moment of its disclosure,

b) is publicly accessible at the time of its disclosure to the receiving Party or it becomes later publicly accessible without the Party’s fault,

c) may be disclosed upon the other Party’s consent expressed in writing otherwise being void,

d) was disclosed to the receiving Party by a third party that was not obliged to keep it confidential or

e) is disclosed by virtue of laws in force.

5. If confidential information needs to be disclosed to a third party for the purpose of performance hereof, the Sponsor or CRO, prior to making any such disclosure, will cause such third party to undertake the confidentiality and non-use obligations in writing at least to the extent applicable to themselves under the Agreement. Any publication of data from the Study or oral presentations on an individual basis with respect to the Study data shall be subject to the Sponsor’s prior review and approval. The Sponsor is entitled at its sole discretion to delay or reject of such publication due to Sponsor’s business or operational reasons.

§ 7. Personal data processing

1. Sponsor undertakes to observe the provisions of Personal Data Protection Act of 29th of August 1997 (uniform text: Journal of Laws from 2002, No. 101, position 926 with later changes) as well as secondary regulations, regarding personal data of CRO’s employees, contractors and other individuals (such as employees of CRO’s contractors), provided by CRO to Sponsor, in

VBL Confidential Information	Page 8 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

the scope of performance the obligations under the Agreement. The personal data of the CRO’s employees, contractors and other individuals will be processed by Sponsor on grounds of their consent or justified purposes of a data controller. However, for the purposes of processing by Sponsor of the personal data of the CRO’s employees or contractors in relation to the execution of obligations of CRO as an employer, CRO entrusts Sponsor with the processing of such personal data in accordance with the Agreement.

2. Sponsor appoints CRO as its representative within the meaning of article 31a of the Personal Data Protection Act.

3. The scope of the entrusted personal data includes the following categories: names, surnames, addresses, contact details, professional experience, current and past position, education, skills. Sponsor undertakes to process the personal data by collecting, recording, storing, deleting compiling, amending, transferring in paper form and by electronic means.

4. Sponsor cannot use entrusted personal data for any other purpose or in any other manner than necessary to execute the Agreement. Sponsor is also obliged neither to disclose nor to pass on the personal data to any entity without prior written CRO’s consent.

5. Sponsor is liable for the damages caused to CRO or any third party in the result of personal data processing against the Agreement by Sponsor or under its responsibility.

6. When the Agreement is finished/terminated/expired, Sponsor is obliged to finish personal data processing, return or destroy all received documents and their copies, and return all received electronic data mediums to CRO.

7. Sponsor entrusts CRO with the processing of personal data of the investigators and the members of study teams for the purposes of the performance of activities connected with the conduct of the Study. The scope of the entrusted personal data includes the following categories: names, surnames, addresses, place of work, telephone numbers, e-mail addresses, bank account numbers, PESEL numbers, tax identification numbers, professional experience, current and past position, education. CRO undertakes to process the personal data by collecting, recording, storing, deleting, compiling, amending, transferring in paper form and by electronic means. Sponsor hereby authorizes CRO to subcontract the processing of the personal data to a further data processor as shall be agreed in advance by the Sponsor.

8. CRO undertakes to observe the provisions of the Personal Data Protection Act and the secondary regulations. CRO cannot use the entrusted personal data for any other purpose or in any other manner than necessary to execute the Agreement.

VBL Confidential Information	Page 9 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

9. In relations between CRO and Sponsor acting as data controllers / data processors towards each other, the following rules shall apply accordingly:

a) the data processor is hereby obliged, prior to commencing the processing of the personal data and afterwards, during the term of this Agreement, to apply any technical and organizational measures that will ensure the security of the personal data being processed, as set forth in the Personal Data Protection Act and the secondary regulations, and any legislation that will supplement and/or replace them in the future; in particular, it should secure the personal data against access by unauthorized persons, its removal by unauthorized persons, and against it being damaged or destroyed;

b) the data processor shall be obliged to ensure supervision of the following: when and by whom the personal data has been entered into the data filing system and to whom the data has been transferred;

c) the data processor undertakes to preserve the confidentiality of the personal data entrusted to it under this Agreement;

d) only persons who were authorized by the data processor shall be allowed to carry out the processing of personal data;

e) the data processor shall be obliged to take all necessary steps to ensure that the persons referred to in point (d) of this clause keep the personal data and the methods of their protection confidential;

f) the data processor shall immediately inform the data controller of any instance of any breach, whatsoever, of the security of the personal data entrusted to the data processor and processed under this Agreement;

g) the data processor shall grant the data controller, at its request, any necessary information concerning all personal data processed by the data processor;

h) the data controller shall have the right to conduct inspections as to whether the data processor is observing the principles of processing the personal data specified in the Personal Data Protection Act, the secondary regulations and this Agreement, by accessing and inspecting any premises where the personal data is processed, as well as the documents, equipment and IT systems relating to the personal data processing;

i) the data controller shall be entitled to review whether the above principles of the processing of the personal data are being observed and as such the data controller’s representatives will be entitled to demand that the data processor’s representatives provide to the data controller

VBL Confidential Information	Page 10 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

the necessary information concerning the way in which the data processor processes the personal data contained in the data filing system;

j) any inspection of whether the above principles of the personal data processing are being observed may only take place after the data controller has notified the data processor of the intention of carrying out such an inspection at least two days in advance of the date of the commencement of the inspection, and has indicated in writing the persons designated to carry out the inspection; an inspection may be exercised by the data controller at the location where the personal data are being processed – between the hours of 9 a.m. and 4 p.m. on any business day;

k) following the inspection, the data controller may draw up recommendations concerning the improvement of the quality of the safeguarding of the personal data, as well as the means of its processing by the data processor and the means of remedying any identified irregularities, which the data processor is obliged to immediately remedy not later than 30 days after the data controller’s notification of its observations;

l) upon the expiry or termination of this Agreement the data processor shall be obliged to transfer the personal data to the data controller or delete all the personal data, within seven days of receiving the data controller’s instruction; the deletion of the personal data shall be understood as the erasing of the personal data, or their modification in such a way that the identity of the persons to whom the data refers cannot be established.

§ 8. Intellectual property

1. The Parties acknowledge that all rights to materials, Investigational Medicinal Product, data bases, notes, analyses, lists, studies or any other documents, as well as names and graphic signs made available to CRO by the Sponsor in any manner whatsoever, shall remain the property of the Sponsor and CRO shall not acquire any rights thereto, except for the right of use thereof during execution of the Agreement for the purpose of conducting the Study in the manner permitted by the Sponsor.

2. Inventions or discoveries whether or not patentable, processes, trade secrets, data, improvements, and/or patents relating to the Investigational Medicinal Product or otherwise arising from the Study, conceived, generated, developed or first reduced to practice, as the case may be, during the term of this Agreement (hereinafter called “Inventions”), either by the CRO,

VBL Confidential Information	Page 11 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

its employees, sites, investigator or any other Sub-contractors related to this Agreement shall be the property of the Sponsor.

3. The CRO its employees, sites, investigator or any other Sub-contractors will promptly inform Sponsor of any Invention or discovery arising from the Study, and assign its rights in relation to all intellectual property rights and know how, and provide reasonable assistance to the Sponsor in filing or prosecuting intellectual property rights, at the expense of the Sponsor.

§ 9. Duration of the Agreement and its termination

1. The Agreement is concluded for a specified period of time and shall be valid from the Effective Date until the termination of the Study unless any circumstances indicated below should occur.

2. Each Party has a right to terminate the Agreement with immediate effect in case of a material breach by the other Party of the obligations resulting from the Agreement if a default is not cured within 30 (thirty) days from the date of delivery of a written notice on the discovered breach to the other Party.

3. The Sponsor has a right to terminate the Agreement upon 90 days’ written notice without giving cause and CRO has a right to terminate the Agreement upon 120 days’ written notice without giving cause.

4. Upon receipt of the notice of termination of the Agreement from the Sponsor by CRO or dispatch of the same to the Sponsor by CRO, CRO shall make all possible efforts to terminate or transfer further conduct of any unfinished Services as soon as possible, according to the Sponsor’s instructions. In such a case, CRO shall cease to provide Services or undertake further obligations in connection with the Services unless Parties agreed otherwise in writing.

5. The Sponsor undertakes an obligation to reimburse CRO for all necessary and actual costs connected with the termination or expiration of the Agreement as well as to pay CRO due remuneration, in particular to reimburse CRO for any expenses incurred (so called „pass through costs”) or to be incurred in relation to provision of the Services from which CRO cannot withdraw. Promptly after the date of the Agreement termination or expiration, CRO shall issue an invoice for the above costs and expenses to the Sponsor.

VBL Confidential Information	Page 12 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

§ 10. Non-Solicitation Clause

1. The Sponsor undertakes an obligation that it shall not employ any employee of the CRO, in its own enterprise or in any company under its control, during the term of the Agreement and for the period of 2 years from the date of termination or expiry hereof.

2. In the event of employing the above mentioned persons, the Sponsor shall be obliged to pay a contractual fine in the amount of Euro 50 000 (say: fifty thousands) per each person employed within 7 days from the receipt of the call for payment. Payment of contractual fine shall not deprive CRO of its right to claim damages exceeding the amount of the contractual fine reserved.

§ 11. Final provisions

1. Neither Party shall be liable to the other Party in connection with this Agreement for any indirect, consequential (including without limitation lost profits), incidental, special or punitive damages.

2. CRO shall not bear any liability connected with the Investigational Medicinal Product, including liability for administering the Investigational Medicinal Product. CRO’s liability due to negligence, non-adherence to professional standards or breach of the Agreement shall be limited to the double amount of the remuneration (CRO fee) received.

3. Sponsor shall defend, indemnify, and hold harmless CRO, its affiliates and their respective directors, officers, employees, consultants, sub-contractors, independent contractors, and agents from and against any and all losses, claims (including third party claims), actions, damages, liabilities, awards, costs and expenses (including reasonable legal counsel fees and expenses), whether joint or several, relating to or arising from or in connection with this Agreement or the Services contemplated herein, including but not limited to, the Study, test, specifications, compound, device, placebo or Investigational Medicinal Product, potential product or procedure performed or administered as a result of the Protocol and this Agreement or any litigation, investigation or other proceeding relating to any of the foregoing, unless as a result of CRO’s its affiliates and their respective directors, officers, employees, consultants, sub-contractors, independent contractors, and agents negligence, non-adherence to professional standards or breach of the Agreement.

4. CRO shall defend, indemnify, and hold harmless Sponsor, its affiliates and its and their respective directors, officers, employees, and agents from and against any and all losses, claims (including third party claims), actions, damages, liabilities, costs and expenses (including

VBL Confidential Information	Page 13 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

reasonable legal counsel fees and expenses) (“Sponsor Losses”) but only to the extent such Sponsor Losses are related to or arise from or in connection with CRO’s negligence, non-adherence to professional standards or breach of this Agreement, except to the extent that such Sponsor Losses arise from (i) the negligence or reckless or willful act or omission of Sponsor, its affiliates or its and their respective directors, officers, employees, contractors or agents; or (ii) any breach of this Agreement by Sponsor, its affiliates, or its and their respective directors, officers, employees, contractors or agents.

5. The Party seeking indemnity will give the indemnifying party prompt written notice (within 15 days knowledge) of any matter upon which such indemnified party intends to base a claim for indemnification (an “Indemnity Claim”). The indemnified party shall have the right to participate jointly with the indemnifying party, at its own expense, in the defense, settlement or other disposition of any Indemnity Claim.

6. In no event shall either Party be liable to the other in case of not being able to perform its obligations hereunder due to a natural disaster, general strike, war, riots, fire, order of the authorities or any other unforeseeable and unpreventable circumstances, provided that such Party unable to perform its obligation will do its best effort to fulfill its obligations. The Party affected by such circumstances shall immediately notify the other Party of this fact in writing, providing any relevant information regarding the matter.

7. No Party may assign any rights or obligations resulting from the Agreement to any third party without prior written consent of the other Party.

8. Any representations of the Parties as specified herein shall be made in writing, otherwise null and void.

9. Except for cases expressly indicated in the Agreement, all statements, notices, calls etc. connected with the Agreement must be delivered to the addresses of the Parties defined in the preamble hereof, otherwise void and ineffective. Either Party should notify the other of the change of its address in accordance with this paragraph. Such notice shall be deemed properly served by the Party after its receipt by the addressee. All and any notices and statements sent thus far in connection with this Agreement to the addresses given above shall be deemed as served effectively.

10. Provisions of § 4, § 6, § 8 and § 10 of the Agreement shall remain in force despite its expiry or termination for any reason.

11. For the avoidance of doubt, this Agreement and the Protocol may only be amended by the agreement in writing of duly authorized signatories of Sponsor and CRO, otherwise being null

VBL Confidential Information	Page 14 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

and void. Changes in the Protocol may imply changes in the total course of the Study (costs, time-lines etc.).

12. If any one or more provisions of this Agreement shall be found to be illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

13. The Agreement and any matters connected herewith shall be governed by the laws of England, excluding its rules for choice of law. Any dispute relating to or arising in connection with this Agreement, which is not settled within a reasonable time, shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (“ICC”) by one arbitrator appointed in accordance with the said rules. The award shall be final and binding and enforceable in any court of competent jurisdiction. The arbitration shall be held in London, United Kingdom, in English language.

14. The Agreement has been drawn up in two identical counterparts, one counterpart for each of the Parties.

CRO:	Sponsor:
Anna Baran /s/ Anna Baran	/s/ Amos Ron
Mike Jagielski /s/ Mike Jagielski	Vascular Biogenics Ltd.
	Amos Ron
	January 1, 2014

VBL Confidential Information	Page 15 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Attachment No. 1

Scope of Services:

Part A

Study Assumptions

STUDY ASSUMPTIONS
Number of countries involved	1
COUNTRIES INVOLVED	Poland
CRA staff involved	3
STUDY SITES	10
PATIENTS ENROLLED (# of expected)	50
NUMBER OF PATIENT’s VISITs IN SITE DURING THE STUDY	9
PLANNED NUMBER OF PAYMENTS FOR PI AND SITES DURING THE STUDY	3

VBL Confidential Information	Page 16 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Attachment No. 1

Scope of Services:

Part B

Division of Responsibilities CRO—Sponsor

	KCR	VBL Ltd.	Comments
STUDY INITIATION
Protocol development		X
Protocol review	X	X	KCR to review the draft of study protocol and provide VBL with comments.
Protocol approval		X
Protocol printing	X
Protocol distribution to sites	X
Preparation of amendments		X
CRF design and development (e CRF)		X
CRF review & approval		X
Preparation of master Informed Consent (IC) and Patient Information Sheet (PIS)		X
Revision and translation of Informed Consent and Patient Information Sheet according to local Ethical Committee requirements	X
Final approval of country specific IC and PIS		X	Based on back translation of local of Informed Consent and Patient Information Sheet. Approval process according to KCR SOP.
Monitoring Plan development	X
Monitoring Plan approval		X
Recruitment Plan development	X
Trial Master File Set-up	X
Distribution of Site Documents	X
Randomization schedule preparation	X

VBL Confidential Information	Page 17 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	KCR	VBL Ltd.	Comments
REGULATORY / ETHICS COMMITTEE SUBMISSIONS
Preparation of the documentation for Ethics Committees	X	X	VBL to provide: - Investigator’s Brochure - IMPD - CRF - Insurance certificate - Patient related scales/diaries - Certificate of analysis - Drug label - Manufacturing authorisation - GMP certificate KCR to provide VBL with country specific requirements regarding submission and to prepare submission package.
Submission of the documentation for Ethics Committees and follow up until authorisation	X
Preparation of the documentation for Regulatory Authorities	X	X	VBL to provide: - Investigator’s Brochure - IMPD - CRF - Insurance certificate - Patient rated scales/diaries - Certificate of analysis
	X	X	- Drug label - Manufacturing authorisation - GMP certificate KCR to provide VBL with country specific requirements regarding submission and to prepare submission package.
Submission of the documentation for Regulatory Authorities and follow up until authorisation	X

VBL Confidential Information	Page 18 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	KCR	VBL Ltd.	Comments
TRANSLATIONS
Translations	X		Relevant for patient-related documents, labels, Power of Attorney
SITE RECRUITMENT AND INITIATION
Investigator’s Site Identification	X
Investigator’s Site Selection	X
Final Site Selection	X	X	KCR to provide VBL with pre-study visit reports and lists of recommended sites in all selected countries. VBL to approve selected sites.
Conduct Site Selection Visits	X
Negotiate Investigators/Sites Contracts	X
Final Approval for Investigators/Sites Contracts		X
Signature on Investigators/Sites Contracts	X
Regulatory Documents collection & review	X
Conduct Site Initiation Visits	X
INVESTIGATOR MEETING
Investigator’s Meeting Planning	X
Investigator’s Meeting Preparation	X	X	VBL to present: - VB-201: Scientific Background - Phase I/II Experience & Development Plan - Study Design & Objectives - Protocol Overview - Eligibility Criteria - Study Specific Procedures - Study Assessment Scales KCR to present: - Communication Plan - Timelines & Recruitment Strategies - ICH GCP Refreshment
Investigator’s Meeting Attendance	X	X

VBL Confidential Information	Page 19 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	KCR	VBL Ltd.	Comments
STUDY DRUG MANAGEMENT/CENTRAL LABORATORY MANAGEMENT
Clinical Trial Supply Logistics Management		X
Packaging and labeling of study medication		X
Distribution of study medication to sites		X
Destruction of unused supplies		X
Randomization list management		X
Central Laboratory Supplies and Logistic Set-up/Courier Management		X	By VBL subcontractor.
Central Laboratory Management		X	VBL subcontractor to manage the central laboratory.
STUDY MONITORING
Conduct Site Monitoring Visits	X
Communication with Sites	X
Monitoring visit reports preparation and review	X
Monitoring visit reports final approval		X
S.D.V.: (100% of patients, 100% of key study parameters)	X
Periodic Regulatory Document Collection / Updates (Investigator’s Master File management)	X
Data review/correction on all CRF’s	X
Resolution of Queries with Sites	X
SAE Reconciliation with Sites	X
Conduct Site Close-out / Termination Visits	X
Drug accountability during study and final drug record reconciliation	X
End of Study Notification to Regulatory Agencies/ECs	X

VBL Confidential Information	Page 20 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	KCR	VBL Ltd.	Comments
CLINICAL STUDY MANAGEMENT
Maintain Central Trial Master File	X
Fortnightly enrolment updates and Weekly Status Reports to Sponsor	X
Administered Investigator’s Payments	X		KCR will be responsible for bank transfers.
Prepare and Distribute Newsletter (if applicable)		X
Central File Archiving		X
Clinical Team Communication	X		KCR to provide Communication Plan.
MEDICAL MONITORING
Development of Medical Monitoring Plan		X
Provide Medical Oversight to CRO Project Team		X
Medical Communication/Consultation with Sites		X
Patient Eligibility - Medical Review		X
Review Safety Data Listing		X
Review CRFs for safety/efficacy		X
Review Safety Laboratory Data		X
Review of Data Management Coding		X
Review of Data Management SAE reconciliation		X
Organization of Data Safety Monitoring Board Meeting		X
SAFETY MONITORING
Safety Plan Preparation		X
SAE Reporting Procedure and Database Set-up		X
Receipt & Review of Initial SAE Report from Site	X
Tracking /Analyzing SAE Report		X
Entering SAE into Database		X
Writing SAE Narrative		X
Expectedness Judgment for SAE & Regulatory Reporting Assessment		X
Final Medical and Regulatory Judgment		X
Preparing Annual Report for Competent Authority in EU (inc. safety update)		X
Reporting Expedited SAEs to Regulatory Authorities		X
Reporting Expedited SAEs to Investigators and EC	X
Ongoing SAE File Maintenance		X

VBL Confidential Information	Page 21 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	KCR	VBL Ltd.	Comments
DATA MANAGEMENT
Preparation of Data Management Documentation such as Data Management Plan, Data Review Plan, Data Handling Guiding		X
EDC collector development		X
Data Review, Query Generation		X
Query Resolution	X
Import of Electronic (Laboratory) Data		X	By VBL subcontractor
Reconciliation of SAEs		X
Provision of data extracts during study to support interim analyses		X
Documentation Maintenance		X
Archiving of EDC tool, Archiving of Data Management Material		X
STATISTICS AND REPORTING
Development of Statistical Analysis Plan		X
Final Approval for Statistical Analysis Plan		X
Creation of Analysis Dataset (Statistical analysis of the dataset)		X
Programming of Tables, Figures and Listings		X
PK parameters calculation		X
Development of interim and final Integrated Statistical/Clinical Report in conformity to ICH guideline and CTD		X
Review of final Integrated Statistical/Clinical Report in conformity to ICH guideline and CTD		X
Final Approval for clinical Study Report		X
Writing of SAE and AE Discontinuation Narratives		X
AUDITS
Conduct of GCP Audits of Investigator’s Sites	X
Conduct of Quality Assurance Audit of Database		X
PROJECT MANAGEMENT
Management of the study team	X
Communication with study sponsor and vendors	X
Coordination of start-up activities, realization phase and closure	X
Oversees the regulatory document collection and submission process.	X
Control and track the budget monthly and cumulative realization	X
Preparation of Risk Management Plan and/or Contingency Plan, if required	X
CONTRACTS AND PAYMENTS
Preparation of study contracts	X
Signature and payments	X	X
Payment of Ethics Committees’ fees	X

VBL Confidential Information	Page 22 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Attachment No. 2

Timelines

STUDY TIMELINES

[***] [***]

VBL Confidential Information	Page 23 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Attachment No. 3

Study Protocol

CLINICAL PROTOCOL

Title:	A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
Protocol No.	VB-201-079
Eudra CT No.:	2012-002763-10
Investigational	VB-201
Product:
Indication:	Plaque Psoriasis
Development	2
Phase:
Sponsor:	Vascular Biogenics Ltd.
	6 Jonathan Netanyahu St.
	Or Yehuda, Israel 60376
	Phone: 972-3-6346450
	Fax: 972-3-6346449
Version:	2.2 (Poland and Israel only)
Date:	December 2, 2013

CONFIDENTIAL

This document contains proprietary and confidential information of VBL. Acceptance of this document constitutes agreement by the recipient that no previously unpublished information contained herein will be published or disclosed without the prior written approval of Vascular Biogenics Limited with the exception that this document may be disclosed to study personnel under your supervision who need to know the contents for conducting the study and appropriate Institutional Review Boards (IRBs)/Ethics Committees (IEC) under the condition that the personnel have agreed to keep this information confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws, however, VBL shall be promptly notified of any such disclosure.

VBL Confidential Information	Page 24 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

AUTHOR SIGNATURE PAGE

The undersigned have written, reviewed and approved the following protocol:

Ron Goldblum, MD	/s/ Ron Goldblum	02 DEC 2013
Medical Monitor	Signature	Date
Vascular Biogenics Ltd
Naamit Sher, PhD	/s/ Naamit Sher	3 Dec 2013
Vice President	Signature	Date
Drug Development & RA
Vascular Biogenics Ltd

VBL Confidential Information	Page 25 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

CONFIDENTIALITY AND INVESTIGATOR STATEMENT

Vascular Biogenics Limited

Clinical Research Protocol

VB-201-079

The information contained in this document and all information provided to you related to VB-201 (“drug”) are the confidential and proprietary information of Vascular Biogenics Limited (Sponsor) and except as may be required by federal, state or local laws or regulations, may not be disclosed to others without prior written permission of Sponsor. The Principal Investigator may, however, disclose such information to supervised individuals working on the Drug, provided such individuals agree to be bound to maintain the confidentiality of such Drug information.

I agree to abide by the statement of confidentiality.

I agree to conduct the study according to this protocol and have read and agree to comply with the Investigator’s Responsibilities. Any changes in procedure will only be made if necessary to protect the safety, rights, or welfare of subjects.

I agree to comply with the current International Conference on Harmonisation (ICH) Guideline on Good Clinical Practice (GCP), applicable laws and regulations, and the Declaration of Helsinki.

I agree to conduct the Study in person or to supervise the Study.

I agree to ensure that all who assist me in the conduct of the Study have access to the Study protocol and any amendments and are aware of their obligations.

Principal Investigator	Date (dd/mmm/yyyy)
Printed Name:
Institution:
Address:

VBL Confidential Information	Page 26 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

TABLE OF CONTENTS

1.0	STUDY SYNOPSIS		31
2.0	LIST OF ABBREVIATIONS		44
3.0	INTRODUCTION		46
	3.1	Psoriasis: Pathophysiology and Unmet Medical Need	46
	3.2	Name and description of the investigational product	46
	3.3	Summary of findings from nonclinical studies relevant to the trial	46
	3.4	Summary of findings from clinical studies	48
		3.4.1     VB-201 Phase I Studies	48
		3.4.2     VB-201 Phase II studies	48
	3.5	Rationale for Route of Administration, Pharmaceutical Form, Dosage, Dosage Regimen and Treatment Period	50
	3.6	Rationale for the PASI 50 Endpoint	50
	3.7	Rationale for the Use of Placebo	51
4.0	OBJECTIVES		52
	4.1	Safety Objective	52
	4.2	Efficacy Objective	52
	4.3	Exploratory Biomarker	52
5.0	INVESTIGATIONAL PLAN		52
	5.1	Study Design	52
	5.2	Number of Patients	52
	5.3	Subject Selection	54
		5.3.1     Inclusion Criteria	54
		5.3.2     Exclusion Criteria	54
	5.4	Subject Screening and Randomization	56
	5.5	Duration of Participation	56
	5.6	Protocol Amendments	56
	5.7	Withdrawal Criteria	56
	5.8	Study/Study Site Termination	57
6.0	STUDY DRUG		57
	6.1	Formulation, Packaging, and Labeling	57
	6.2	Storage and Handling	58
	6.3	Accountability	58

VBL Confidential Information	Page 27 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

	6.4	Access to Blinded Treatment	58
	6.5	Administration of Study Drug	59
		6.5.1     Dosage	59
		6.5.2     Assignment of Treatment Cartons	60
		6.5.3     Compliance	60
7.0	PRIOR AND CONCOMITANT MEDICATION		60
8.0	OUTCOME MEASURES		61
	8.1	Efficacy Assessments	61
	8.2	Safety Assessments	64
		8.2.1     Physical Examination Assessments	64
		8.2.2     Clinical Laboratory & Other Safety Assessments	64
		8.2.3     Population Pharmacokinetics	65
		8.2.3.1     Blood and Urine Samples	66
		8.2.3.2     Risk Assessment	66
		8.2.4     Study Withdrawals	66
		8.2.5     Adverse Events and Serious Adverse Events	66
	8.3	Exploratory Assessments	66
		8.3.1     Inflammatory Related Biomarkers	67
9.0	SCHEDULE OF STUDY ASSESSMENTS		67
	9.1	Screening Visit	67
	9.2	Baseline	67
	9.3	Week 2	68
	9.4	Week 4, 8, 12	69
	9.5	Week 16	69
	9.6	Week 20	70
	9.7	Week 24/ Early Termination	70
	9.8	Week 28	71
10.0	ADVERSE EVENTS		71
	10.1	Definition of Adverse Event	71
	10.2	Definition of Serious Adverse Event	72
	10.3	Reporting and Documentation	73
	10.4	Patient Stopping Rules	74
	10.5	Pregnancy	75
11.0	STATISTICAL CONSIDERATIONS		75

VBL Confidential Information	Page 28 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

	11.1	Statistical Methods		75
		11.1.1	Comparisons of Interest	75
		11.1.2	Sample Size Determination	75
		11.1.3	Subject Population/Data Sets To Be Evaluated	75
		11.1.3.1       Modified Intent-To-Treat (MITT) Population		75
		11.1.3.2       Per-Protocol Population		76
		11.1.3.3       Safety Population		76
		11.1.4	Randomization	76
	11.2	Statistical Analyses		76
		11.2.1	Subject Disposition	77
		11.2.2	Demography	77
		11.2.3	Efficacy Analysis	77
		11.2.3.1       Primary Efficacy Endpoints		77
		11.2.3.2       Secondary Efficacy Endpoints		78
		11.2.3.3       Tertiary Endpoints		79
		11.2.4	Safety Analysis	80
		11.2.4.1       Adverse Events		80
		11.2.4.2       Laboratory Parameters		80
		11.2.4.3       Vital Signs		81
		11.2.4.4       Withdrawals		81
		11.2.4.5       Deaths		81
		11.2.4.6       Dropouts		81
		11.2.5	Concomitant Medications	81
12.0	DATA RECORDING, MONITORING, AND RETENTION			81
	12.1	Source Documents		81
	12.2	Case Report Forms (CRFs)		81
	12.3	Record Retention		81
	12.4	Monitoring Requirements		82
	12.5	Subject Confidentiality		82
13.0	ETHICS			83
	13.1	Ethical Conduct of the Study		83
	13.2	Local Regulatory Approval		83
	13.3	Ethics Committee Approval		84
	13.4	Subject Information and Informed Consent		84

VBL Confidential Information	Page 29 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

14.0         PUBLICATION	85
15.0         LIST OF APPENDICES	85
16.0         REFERENCES	87
LIST OF TABLES
Table 1: Schedule of Procedures for VB-201-079 (Psoriasis)	42
Table 2. Composition of the patient identification number	53
Table 3. Composition of the randomization number	53
Table 4. VB-201 Drug Distribution	59
Table 5. Clinical Assessments Relating to Efficacy	62
Table 6. Physical Examination Assessments Relating to Safety	64
Table 7. Clinical Laboratory & Other Assessments Relating to Safety	65
Table 8. Population Pharmacokinetics	66
Table 9. Clinical Laboratory for Exploratory Assessments	66

VBL Confidential Information	Page 30 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

1.0         STUDY SYNOPSIS

Title of Study:	A Randomized, Double-Blind, Dose-Ranging, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
Sponsor:	VBL
Phase:	Phase 2
Patient Population:	Male or female patients >18 to <75 of age with moderate to severe, stable, active plaque Psoriasis Vulgaris affecting between 10% to 30% of the body surface and with a Psoriasis Area and Severity Index (PASI) score of 10 to 20
Efficacy Objective:	To examine the effect of treatment with two different doses of VB-201 compared to placebo for 16 weeks and 24 weeks on measures of disease activity in patients with psoriasis.
Safety Objective:	To examine the safety and tolerability of up to 24 weeks’ treatment with VB-201 vs. placebo in patients with psoriasis.
Study Design:	[***]

VBL Confidential Information	Page 31 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Dosage Regimen and Treatment Groups	[***]
Investigative Product Name and Description	[***]
Number of Subjects:	;[***]
Duration of Participation:	[***]

VBL Confidential Information	Page 32 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Eligibility Criteria Inclusion Criteria	[***]
Exclusion Criteria	[***]

VBL Confidential Information	Page 33 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

4. [***]

VBL Confidential Information	Page 34 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

	[***]
Concomitant	[***]

VBL Confidential Information	Page 35 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Medications:		[***]
Safety Endpoints:		[***]
Stage 1 Primary Efficacy Endpoint:		[***]
Stage 1 Secondary Endpoints:	1.	[***]

VBL Confidential Information	Page 36 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

		[***]
Stage 1 Tertiary Endpoints:	1.	[***]

VBL Confidential Information	Page 37 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Stage 2 Primary Efficacy Endpoint: [***]

VBL Confidential Information	Page 38 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Stage 2 Secondary Endpoints:	1.	[***]
Stage 2 Tertiary Endpoints:	1.	[***]

VBL Confidential Information	Page 39 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

	4.	[***]
Compliance Measures		[***]
Study Conduct		[***]
Statistical Methods		[***]

VBL Confidential Information	Page 40 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Rationale for Number of Subjects:     [***]

VBL Confidential Information	Page 41 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Table 1: Schedule of Procedures for VB-201-079 (Psoriasis)

Evaluation	[***]			[***]	[***]	[***]	[***]	[***]	[***]	[***]
				STAGE 1				STAGE 2
Study Day		[	***]	[***]	[***]	[***]	[***]	[***]	[***]	[***]
Assessment Window (±Days)					[***]	[***]	[***]	[***]	[***]	[***]
Informed Consent		X
Inclusion/ Exclusion Criteria		X		X
[***]		X
[***]		X1		X			X		X
[***]		X		X			X		X
[***]		X		X		X	X	X	X	(X)3
[***]				X		X	X	X	X
[***]				X		X4	X		X
[***]		X					X		X
[***]		X5		X6			X		X
[***]		X		X7		X	X	X	X	X
[***]				X		X	X	X
[***]						X	X	X	X
[***]						X	X	X	X
[***]		X		X	X	X	X	X	X	X
[***]				X	X	X	X	X	X	X
[***]8		X		X		X	X	X	X	X
[***]				X			X		X
[***]				X			X		X	X

¹  [***]

VBL Confidential Information	Page 42 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Figure 1. STUDY DIAGRAM

VBL Confidential Information	Page 43 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

2.0 LIST OF ABBREVIATIONS

Abbreviation/ Acronym	Definition
AE	Adverse Event
ALT	Alanine transaminase
ANCOVA	Analysis of Covariance
AST	Aspartate transaminase
BSA	Body Surface Area
BUN	Blood Urea Nitrogen
CFR	Code of Federal Regulations
CRA	Clinical Research Associate
CRF	Case Report Form
CRO	Contract Research Organization
DLQI	Dermatology Life Quality Index
DSM-LV-TR	Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
ECG	Electrocardiogram
eCRF	Electronic Case Report Form
EDC	Electronic Data Capture
ET	Early Termination
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GGT	Gamma Glutamyl Transferase
Hb	Hemoglobin
HIPAA	Health Insurance Portability and Accountability Act
HIV	Human Immunodeficiency Virus
ICH	International Conference on Harmonization
IEC	Independent Ethics Committee
IL	Interleukin
IRB	Institutional Review Board
IUD	Intrauterine Device
IVRS / IWRS	Interactive Voice Response System/Interactive Web Response
LOCF	Last Observation Carried Forward
MCH	Mean Corpuscular Hemoglobin
MCHC	Mean Corpuscular Hemoglobin Concentration
MCV	Mean Corpuscular Volume

VBL Confidential Information	Page 44 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Abbreviation/ Acronym	Definition
MedDRA	Medical Dictionary for Regulatory Activities
MITT	Modified Intent-To-Treat
PASI	Psoriasis Area and Severity Index
PBMC	Peripheral Blood Mononuclear Cells
PGA	Physician Global Assessment
PIF	Pregnancy Information Form
PK	Pharmacokinetics
PO	By Mouth
QD	Once Daily
RBC	Red Blood Cell
SAE	Serious Adverse Event
SUSAR	Suspected Unexpected Serious Adverse Reaction
TNF-a	Tumor Necrosis Factor-a
ULN	Upper Limit of Normal
URI	Upper Respiratory Infection
UTI	Urinary Tract Infection
VAS	Visual Analogue Scale
VBL	Vascular Biogenics Ltd.
WBC	White Blood Cell
WHO	World Health Organization

VBL Confidential Information	Page 45 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

3.0 INTRODUCTION

3.1 Psoriasis: Pathophysiology and Unmet Medical Need

Psoriasis is a life-long, immune-mediated inflammatory skin disease of unknown etiology, affecting up to 3% of the general population, with rates varying among geographic areas and races.¹ Over 80% of patients have chronic plaque psoriasis, characterized by recurrent exacerbations and remissions of thickened, erythematous, scaly patches of skin that can occur anywhere on the body.

Psoriatic symptoms can cause physical discomfort (pain and pruritus), and when combined with the psychological effects of the disease often interfere with everyday activities and negatively impact a patient’s quality of life.^2,3 While there are many available treatments, these agents each have limited efficacy and/or significant side effects. Thus, there remains a significant unmet need for a therapy that will provide high continuous efficacy and improved safety profile.

It is currently believed that environmental factors, including microorganisms, instigate a cascade of events which lead to psoriasis initiation. ⁴ Once encountered by microbial components, toll-like receptors (TLR) expressed on keratinocytes and dermal dendritic cells mediate the secretion of pro-inflammatory cytokines such as IL-6, IL-1, IL-12 and IL-23.^5,6 These cytokines induce the generation of Th1 and Th17 cells which promote psoriasis pathogenesis.^7,8,9

Vascular Biogenics Ltd (VBL) has developed a small molecule, VB-201 (formerly known as CI-201 as seen in some of the figures) a new class of compounds, oxidized phospholipid analogs (lecinoxoids). VB-201 was found to inhibit TLR signaling restricted to TLR2 and TLR4, an effect attributed to its binding to TLR2 and CD14. Consequently, when activated using TLR4 and TLR2 agonists in the presence of VB-201, antigen presenting cells showed impaired production of the Th1 and Th17- polarizing cytokines IL-12(p40) and IL-6 respectively.

Given the putative TLR complicity in psoriasis, VB-201 has the potential to be an orally active drug for treating psoriasis.

The current study is designed to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with chronic plaque psoriasis.

3.2 Name and description of the investigational product

[***]

3.3 Summary of findings from nonclinical studies relevant to the trial

[***]

VBL Confidential Information	Page 46 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

5) [***]

[***]

VBL Confidential Information	Page 47 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

3.4 Summary of findings from clinical studies

3.4.1 VB-201 Phase I Studies

[***]

3.4.2 VB-201 Phase II studies

VB-201 was further used in two Phase II clinical trials:

1. [***]

VBL Confidential Information	Page 48 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

2. VB-201-030: [***]

VBL Confidential Information	Page 49 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

3.5 Rationale for Route of Administration, Pharmaceutical Form, Dosage, Dosage Regimen and Treatment Period

[***]

3.6 Rationale for the PASI 50 Endpoint

[***]

VBL Confidential Information	Page 50 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

3.7 Rationale for the Use of Placebo

[***]

VBL Confidential Information	Page 51 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

4.0 OBJECTIVES

4.1 Safety Objective

• To examine the safety and tolerability of up to 24 weeks’ treatment with VB-201 or placebo in patients with psoriasis.

4.2 Efficacy Objective

• Stage 1: To examine the effect of treatment with two different doses of VB-201 compared to placebo (initial 16 weeks) on measures of disease activity in patients with psoriasis.

• Stage 2: To examine the effect of treatment with two different doses of VB-201 compared to placebo (24 weeks) on measures of disease activity in patients with psoriasis.

4.3 Exploratory Biomarker

• [***]

5.0 INVESTIGATIONAL PLAN

5.1 Study Design

[***]

5.2 Number of Patients

[***]

VBL Confidential Information	Page 52 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

Table 2. Composition of the patient identification number

	Combined site number
Letter	Country number		Site number	Patient number
S	Germany	01	Site numbers will be assigned in an ascending order: 01, 02, 03, 04…	Patient numbers will be assigned in an ascending order: 01, 02, 03, 04,…
	Spain	02
	Israel	03
	Poland	04

The 7-digit randomization number is a combination of the letter R (1 digit), the combined site number (4 digits), consisting of the country number (2 digits) and the site number (2 digits) and the patient number (2 digits). The site number is identical to the site number of the patient identification number. Patient numbers of the randomization number will start with 51 to ensure clear distinction from patient identification numbers. Example: R010151 is the site number 0101 and the patient number 51. Refer to Table 3 below.

Table 3. Composition of the randomization number

	Combined site number
Letter	Country number		Site number	Patient number
R	Germany	01	Site numbers will be assigned in an ascending order: 01, 02, 03, 04…	Patient numbers will be assigned in an ascending order: 51, 52, 53, 54,…
	Spain	02
	Israel	03
	Poland	04

VBL Confidential Information	Page 53 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

5.3 Subject Selection

5.3.1 Inclusion Criteria

[***]

5.3.2 Exclusion Criteria

Patients who meet ANY of the following criteria will be excluded from participation in this study:

1. [***]

VBL Confidential Information	Page 54 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

• [***]

12 [***]

VBL Confidential Information	Page 55 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

5.4 Subject Screening and Randomization

[***]

5.5 Duration of Participation

[***]

5.6 Protocol Amendments

[***]

5.7 Withdrawal Criteria

[***]

VBL Confidential Information	Page 56 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

5.8 Study/Study Site Termination

[***]

6.0 STUDY DRUG

6.1 Formulation, Packaging, and Labeling

[***]

VBL Confidential Information	Page 57 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

6.2 Storage and Handling

The study drug should be stored on site at room temperature, in a secured location with access limited to authorized personnel. All boxes of study drug, both used and unused, must be saved for a drug audit by the Sponsor clinical monitor or an assigned designee. Once dispensed to the study subjects the study drug should be stored at room temperature. Subjects should be instructed on the proper storage methods and conditions.

6.3 Accountability

Study drug (VB-201 and placebo) will be supplied by the Sponsor. It is the responsibility of the Principal Investigator to supervise accurate monitoring of the receipt, storage, dispensing, and accounting of all study drug according to accepted medical and pharmaceutical practice.

Copies of all invoices of study drug shipments must be retained. Accurate, original site records of study drug inventory and dispensing must be maintained using the forms provided. All shipment, accountability, and dispensing records must be made available for inspection by the Sponsor or the designated CRO upon request.

Each site must keep all used and unused cartons in their original kit packaging until the Study Monitor either arranges return to the distribution center or gives instruction on their disposal. If any unused cartons remain at the end of the study, they will be accounted for at the Site Close-Out Visit in the presence of the Study Monitor, who will provide instructions on their disposal. If the Study Monitor directs the site to dispose of study drug or empty blister packs, disposal should be according to the institution standard operating procedures and all applicable local and national regulations.

6.4 Access to Blinded Treatment

A subject’s treatment assignment should only be unblinded when knowledge of the treatment is essential for the further management of the subject. Unblinding for any other reason will be considered a protocol violation.

VBL Confidential Information	Page 58 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

The Principal Investigator should make every effort to contact either the CRO or the Sponsor before unblinding any subject’s treatment assignment, but must do so within one working day after the event and must document the unblinding in the subject’s source documentation.

The identity of the treatment group assigned to subjects can be provided, in an emergency only, by the centralized randomization system via the CRO. The Principal Investigator or his/her designee is responsible for ensuring that the instructions on how to perform a code break are stored safely, that their location is known, and that access is readily available to the relevant staff in case of an emergency. A separate Sponsor representative who is not involved with the study will also have access to unblinding information if required.

The CRO’s safety officer will report SUSARs on the Sponsor’s behalf and will break the blind for SUSAR reporting.

6.5 Administration of Study Drug

6.5.1 Dosage

[***]

Table 4. VB-201 Drug Distribution

VBL Confidential Information	Page 59 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Treatment Group	Carton AM	Carton PM
[***]	[***]	[***]

Subjects will be instructed to take 2 capsules from the morning blister (white) pack at breakfast time with food and 2 capsules from the evening blister (silver) pack at dinner time with food every day for up to 24 weeks.

Each carton will be labeled to meet regional regulatory requirements. All capsules will be identical in appearance. There is no provision under this protocol for dose adjustments by the Investigator.

6.5.2 Assignment of Treatment Cartons

At each visit, the Investigator or designee will first assess the subject to confirm eligibility to continue to receive study drug. After eligibility is confirmed, study medication with the appropriate subject number can be distributed to the subject [***]

6.5.3 Compliance

[***]

7.0 PRIOR AND CONCOMITANT MEDICATION

[***]

VBL Confidential Information	Page 60 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

8.0 OUTCOME MEASURES

8.1 Efficacy Assessments

[***]

VBL Confidential Information	Page 61 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Table 5. Clinical Assessments Relating to Efficacy

Assessment	Study Visit	Description
[***]	[***]	[***]

VBL Confidential Information	Page 62 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Table 5. Clinical Assessments Relating to Efficacy (cont.)

Assessment	Study Visit	Description
[***]	[***]	[***]

W-week, D-day, ET-early termination

[***]

VBL Confidential Information	Page 63 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Plaque Photography

[***]

8.2 Safety Assessments

8.2.1 Physical Examination Assessments

The physical exam assessments relating to safety to be performed during the study are described in Table 6.

Table 6. Physical Examination Assessments Relating to Safety

Assessment	Study Visit	Description
[***]	[***]	[***]

W-week, D-day, ET-early termination

8.2.2 Clinical Laboratory & Other Safety Assessments

The clinical laboratory and other tests relating to safety to be performed during the study are described in Table 7.

VBL Confidential Information	Page 64 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Table 7. Clinical Laboratory & Other Assessments Relating to Safety

Assessment	Study Visit	Description
[***]	[***]	[***]

W-week, D-day, ET-early termination

* If values are abnormal at the Week 24/ET visit, they should be repeated at the Week 28 visit to ensure values have returned to within normal limits.

8.2.3 Population Pharmacokinetics

Blood collected for trough levels of VB-201 during the study are described in Table 8:

VBL Confidential Information	Page 65 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Table 8. Population Pharmacokinetics

Assessment	Study Visit	Description
[***]	[***]	[***]

8.2.3.1 Blood and Urine Samples

[***]

8.2.3.2 Risk Assessment

[***]

8.2.4 Study Withdrawals

[***]

8.2.5 Adverse Events and Serious Adverse Events

Adverse events and serious adverse events (SAEs) are discussed in detail in Section 9.

8.3 Exploratory Assessments

The clinical laboratory and other tests relating to exploratory assessments to be performed during the study are described in Table 9:

Table 9. Clinical Laboratory for Exploratory Assessments

Assessment	Study Visit	Description
[***]	[***]	[***]

D- day, W-week, ET-early termination

VBL Confidential Information	Page 66 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

8.3.1 Inflammatory Related Biomarkers

[***]

9.0 SCHEDULE OF STUDY ASSESSMENTS

[***]

9.1 Screening Visit

[***]

9.2 Baseline

[***]

VBL Confidential Information	Page 67 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

• [***]

NOTE: [***]

9.3 Week [***]

Each subject will be contacted by telephone at Week [***] and the following will be performed:

VBL Confidential Information	Page 68 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

• [***]

9.4 Week [***]

Each of the following assessments will be performed on Week, [***]

• [***]

9.5 Week [***]

Each of the following assessments will be performed on Week [***]:

• [***]

VBL Confidential Information	Page 69 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

• [***]

9.6 Week [***]

Each of the following assessments will be performed on Week [***]

• [***]

9.7 Week [***]

Each of the following assessments will be performed at Week [***] or, if a subject discontinues early from the study:

• [***]

VBL Confidential Information	Page 70 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

• [***]

9.8 Week [***]

Patients who complete the Week [***] and those who discontinue early from the study will return to the clinic on Week [***] after their last study medication dose if the subject discontinued early from the study, for a follow-up evaluation and the following assessments:

• [***]

10.0 Adverse Events

10.1 Definition of Adverse Event

[***]

VBL Confidential Information	Page 71 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

Severity Assessment

[***]

Causality Assessment

[***]

10.2 Definition of Serious Adverse Event

[***]

VBL Confidential Information	Page 72 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

• [***]

10.3 Reporting and Documentation

The Investigator must report all directly observed AEs and all spontaneously reported AEs. At each visit the Investigator will ask the subject a nonspecific question (e.g., “Have you noticed anything different since your last visit?”) to assess whether any AEs have been experienced since the last report or visit. AEs will be identified and documented on the AE page of the CRF in appropriate medical terminology. Details of the event must include severity, relationship to study drug, duration, action taken, and outcome.

The action(s) taken regarding the AE are classified as follows:

Treatment for event

• None

• Concomitant medication given or changed

• Hospitalization

• Others

• Unknown (only applicable if patient has been lost to follow up).

Action taken with study medication

• None

VBL Confidential Information	Page 73 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

• Temporary discontinuation

• Permanent discontinuation

• Unknown (only applicable if patient has been lost to follow up).

The outcome of the AE is classified as follows

• Recovered

• Recovered with sequelae

• Not recovered

• Death

• Unknown (only applicable if patient has been lost to follow up).

Furthermore it must be stated if the study was discontinued permanently for patient (yes, no) due to the AE/ SAE

The Principal Investigator is responsible for evaluating all AEs, obtaining supporting documents, and determining that documentation of the event is adequate. The Principal Investigator may delegate these duties to Sub-investigators and must assure that these Sub-investigators are qualified to perform these duties under the supervision of the Principal Investigator.

In the event that a subject is withdrawn from the study because of an AE, it must be recorded on the CRF. The subject should be followed and treated by the Investigator until the AE has resolved or a new chronic baseline has been established.

Any SAE, whether or not considered related to the study drug, must be reported immediately (within 24 hours) upon learning of the event (See Study Manual). The Investigator or his designee should complete the study-specific SAE Report Form. Investigators should not wait to collect additional information that fully documents the event before notifying VBL or its designee of an SAE. Contact numbers for reporting SAEs and events of concern will be provided prior to the start of the study.

It is the responsibility of the Investigator to report SAEs to their IRB/IEC according to the standard operating procedures and policies of the IRB or EC. At a minimum, events identified by the Sponsor to require expedited reporting as serious, unexpected, and possibly related to study drug must be brought to the attention of the responsible IRB/IEC. Adequate documentation must be provided to VBL or its designee that the IRB or EC was properly notified.

10.4 Patient Stopping Rules

The following stopping rules will be utilized in this study:

1. [***]

VBL Confidential Information	Page 74 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

2. [***]

Subjects who permanently discontinue study medication shall return for an Early Termination visit and subsequently for a final safety visit 4 weeks from the last dose.

10.5 Pregnancy

[***]

11.0 STATISTICAL CONSIDERATIONS

11.1 Statistical Methods

11.1.1 Comparisons of Interest

[***]

11.1.2 Sample Size Determination

[***]

11.1.3 Subject Population/Data Sets To Be Evaluated

11.1.3.1   Modified Intent-To-Treat (MITT) Population

[***]

VBL Confidential Information	Page 75 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

11.1.3.2 Per-Protocol Population

[***]

11.1.3.3 Safety Population

[***]

11.1.4 Randomization

[***]

11.2 Statistical Analyses

[***]

VBL Confidential Information	Page 76 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

11.2.1 Subject Disposition

[***]

11.2.2 Demography

[***]

11.2.3 Efficacy Analysis

[***]

11.2.3.1 Primary Efficacy Endpoints

11.2.3.1.1 Stage 1 Primary Efficacy Endpoints

[***]

11.2.3.1.2 Stage 2 Primary Efficacy Endpoints

[***]

VBL Confidential Information	Page 77 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

11.2.3.2 Secondary Efficacy Endpoints

11.2.3.2.1  Stage 1 Secondary Efficacy Endpoints

[***]

11.2.3.2.2  Stage 2 Secondary Efficacy Endpoints

[***]

VBL Confidential Information	Page 78 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

3. [***]

11.2.3.3 Tertiary Endpoints

11.2.3.3.1  Stage 1 Tertiary Endpoints

[***]

4. [***]

11.2.3.3.2  Stage 2 Tertiary Endpoints

[***]

VBL Confidential Information	Page 79 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

[***]

11.2.4 Safety Analysis

[***]

11.2.4.1 Adverse Events

[***]

11.2.4.2 Laboratory Parameters

[***]

VBL Confidential Information	Page 80 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

11.2.4.3 Vital Signs

[***]

11.2.4.4 Withdrawals

[***]

11.2.4.5 Deaths

All deaths will be listed.

11.2.4.6 Dropouts

Dropout rates due to rescue intervention in each of the VB-201 groups will be compared to the placebo group using Fisher’s exact test.

11.2.5 Concomitant Medications

[***]

12.0 DATA RECORDING, MONITORING, AND RETENTION

12.1 Source Documents

Source records are original documents, data, and records (e.g., medical records, raw data collection forms, pharmacy dispensing records, recorded data from automated instruments, laboratory data) that are relevant to the clinical trial. The Investigator will prepare and maintain adequate and accurate source documents. These documents are designed to record all observations and other pertinent data for each subject enrolled in this clinical trial. Source records must be adequate to reconstruct all data transcribed onto the Case Report Forms (CRFs).

12.2 Case Report Forms (CRFs)

All data will be recorded on electronic data capture (EDC) system CRFs provided by the Sponsor or its designee. All electronic case report forms (eCRFs) should be completed by designated study personnel in a timely fashion.

All missing data must be explained in the subject’s source record. All eCRFs must be reviewed and verified by the investigator for accuracy, completeness, legibility, and timeliness of reporting to the Sponsor.

12.3 Record Retention

Investigators are required to maintain all study documentation, informed consent forms and subject information sheets and adequate records for the receipt and disposition of all study drugs in a secure and safe facility.

VBL Confidential Information	Page 81 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Essential documents must be retained for at least 2 years following the FDA or other regulatory approval date of the drug, or until two years after the drug investigational program is discontinued unless a longer period is required by applicable law or regulation. Only the Sponsor can notify an Investigator when any records may be discarded. If the investigator wishes to assign responsibility for the study records to another party or have them moved to another location, the Sponsor must be notified in advance. When the study documents no longer need to be retained, it is the responsibility of the Sponsor to inform the investigator/institution. Subject identity information will be maintained for 15 years unless a longer period is required by applicable law or regulation.

12.4 Monitoring Requirements

Following pre-qualification and initiation of the study site, periodic monitoring visits will be made by the Sponsor or its designated representative. The investigator must provide sufficient space and allocate sufficient time for the monitor to inspect subject source records, case report forms, drug accountability records, and regulatory documents.

The study monitor is responsible for visiting the study site at regular intervals to verify the following:

• The rights and well-being of human Patients are protected;

• The reported data are accurate, complete, and verifiable from source documents;

• The conduct of the trial is in compliance with the currently approved protocol, amendment(s), International Conference on Harmonisation (ICH) Good Clinical Practices (GCP), U.S. Food and Drug Administration (FDA) Code of Federal Regulations (CFR), and any other applicable national and local regulatory requirements.

The study monitor should have access to subject medical records and other study-related records needed to verify the entries in the database.

The Investigator must make study data accessible to the study monitor, the Sponsor, authorized representatives of the Sponsor (e.g., CRO), and Regulatory Agencies/Competent Authorities upon request.

12.5 Subject Confidentiality

The Investigator must ensure that the subject’s anonymity is maintained. On the CRFs or other documents submitted to the Sponsor and/or designated CRO, Patients should be identified by a Subject Identification number and/or randomization number.

Documents that are not for submission to the Sponsor and/or designated CRO (e.g., signed informed consent forms and subject information sheets) should be kept in strict confidence by the Investigator in compliance with Federal regulations/ICH GCP Guidelines. It is required that the Investigator and institution permit authorized representatives of the company, of the regulatory agency, and the IRB/IEC direct access to review the subject’s original medical records for verification of study-related procedures and data.

Direct access includes examining, analyzing, verifying, and reproducing any records and reports that are important to the evaluation of the study. The Investigator is obligated to inform the subject that his/her study-related records will be reviewed by the above named

VBL Confidential Information	Page 82 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

representatives, although the confidentiality of his/her records will be maintained as much as reasonably possible.

For the purposes of the study, only the data set forth in this protocol (including the CRFs) will be obtained regarding participating Patients (whether screen failures or enrolled Patients). Such data shall:

• be processed in accordance with this Protocol or as otherwise instructed by the Sponsor;

• be processed solely for the purposes of the study and in the manner specified in this Protocol;

• not be processed in any manner incompatible with the purposes of the study;

• be accurate, up to date and corrected to address any inaccuracies or omissions;

• be maintained (as specified in this Protocol/using reasonable measures) to protect against accidental or unlawful destruction, accidental loss or damage, alteration, unauthorized disclosure or access and against other unauthorized or unlawful forms of processing;

• not be disclosed to any third party without the Sponsor’s prior written consent; and

• be maintained as detailed in Section 12.3 unless a longer period is required by applicable laws or regulations.

Any reasonably requested assistance shall be provided to assist the Sponsor to enable it to comply with any data-related notification obligations under applicable laws or regulations. In the US, conduct of this study will comply with all provisions of HIPAA. The Sponsor shall be promptly informed of any communication received from a study subject regarding the data collected about him/her in connection with the study.

13.0 ETHICS

13.1 Ethical Conduct of the Study

The study will be conducted in accordance with applicable national and international laws and regulations, the ICH-GCP guideline and the ethics principles that have their origins in the Declaration of Helsinki. The protocol and the proposed informed consent form have to been reviewed and approved by a properly constituted Independent Ethics Committee (IEC/IRB) before study start at a particular study site. Prior to study start, the principal investigator is required to sign the protocol signature page (page 3 of this study protocol) confirming his agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to monitors, auditors, IRBs/IECs, and regulatory authorities as required.

13.2 Local Regulatory Approval

The Sponsor or the CRO will supply the Competent Authorities of each participating country with a dossier containing the required pharmacological, toxicological and pharmaceutical data on the compound, so as to obtain import and study approval. The study will not start in that country until this has been obtained where appropriate.

VBL Confidential Information	Page 83 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

13.3 Ethics Committee Approval

The Principal Investigator at each site is responsible for obtaining Institutional Review Board (IRB) or Independent Ethics Committee (IEC), approval for the protocol, informed consent form/ information sheet, and any advertisements to recruit Patients before being implemented at the investigative site. Written approval of these documents must be obtained from the committee before any subject is enrolled at a center.

The Principal Investigator is also responsible for the following interactions with the IRB/IEC:

• Obtaining IRB/IEC approval for any protocol amendments and informed consent form revisions before implementing the changes;

• Providing the IRB/IEC with any required information before or during the study;

• Submitting progress reports to the IRB/IEC, as required, during the conduct of the study; requesting re-review and approval of the study, as needed; providing copies of all IRB/IEC re-approvals and relevant communication to the CRO or the Sponsor;

• Notifying the IRB/IEC of all serious and unexpected AEs related to the study drug reported by the Sponsor or the CRO, as required. Documentation of this notification should be retained.

13.4 Subject Information and Informed Consent

No investigator may involve a human being as a subject in research unless the Investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. An Investigator shall seek such consent only under circumstances that provide the prospective subject or the subject’s legally authorized representative sufficient opportunity to consider whether or not to participate, and that minimize the possibility of coercion or undue influence. The information that is given to the subject or the representative shall be in a language understandable to the subject or representative.

The Sponsor or its designated representative will provide the Investigator with a sample consent form. Local and/or institutional requirements may require disclosure of additional information in the informed consent. Any changes to the consent form must be submitted to the sponsor or its designated representative for approval prior to submission to the IRB/IEC. The IRB/IEC must review the consent form for approval/favorable opinion, and a copy of the approved consent form must be submitted to the Sponsor or its designated representative prior to initiation of the study.

Before implementing any study procedure, informed consent shall be documented by the use of an IRB/IEC approved written consent form signed and dated by the subject or the subject’s legally authorized representative at the time of consent. A copy of the signed informed consent will be given to the subject or the subject’s legally authorized representative. The original signed consent must be maintained by the Investigator and available for inspection by the Sponsor, its designated representative, or regulatory authority at any time.

VBL Confidential Information	Page 84 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

14.0 PUBLICATION

The Sponsor recognizes the importance of communicating clinical study data and therefore it is the intent of the Sponsor to publish the results of this trial, the details of which will be provided in the Clinical Study Agreement.

15.0 LIST OF APPENDICES

Appendix A: ELEMENTS OF THE PSORIASIS AREA AND SEVERITY INDEX (PASI)

VBL Confidential Information	Page 85 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

Appendix A: ELEMENTS OF THE PSORIASIS AREA AND SEVERITY INDEX (PASI)

	Head	Upper Extremities	Trunk	Lower extremities
[***]
[***]
[***]
[***]
[***]
[***]
[***]	[***]	[***]	[***]	[***]
[***]

[***]

VBL Confidential Information	Page 86 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

16.0 REFERENCES

1. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994;102(6):14S-8S.

2. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-92.

3. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45(3):155-9.

4. Nestle FO, Kaplan DH, Barker J. Mechanisms of Disease: Psoriasis. N Engl J Med 2009 Jul;361:496-509.

5. Nestle FO, Di Meglio P, Qin JZ. Skin immune sentinels in health and disease. Nature Reviews Immunology 2009
Oct;9:679-690.

6. Di Meglio P, Perera GK, Nestle FO. The Multitasking Organ: Recent Insights into Skin Immune Function. Immunity 2011 Dec;35: 857-869.

7. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999 Nov;113(5):752-9.

8. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994 Feb;102(2):145-9.

9. Fitch E, Harper E, Skorcheva I, et al. A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007 Dec;9(6):461- 7.

10. Vascular Biogenics Ltd. VB-201 Investigator’s Brochure Version 13. Internal archive; 2012.

VBL Confidential Information	Page 87 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Protocol VB-201-079	VB-201

CLINICAL PROTOCOL

Title:	A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
Protocol No.	VB-201-079
Eudra CT No.:	2012-002763-10
Investigational Product:	VB-201
Indication:	Plaque Psoriasis
Development Phase:	2
Sponsor:	Vascular Biogenics Ltd.
	6 Jonathan Netanyahu St.
	Or Yehuda, Israel 60376
	Phone: 972-3-6346450
	Fax: 972-3-6346449
Version:	2.2 (Poland and Israel only)
Date:	December 2, 2013

CONFIDENTIAL

This document contains proprietary and confidential information of VBL. Acceptance of this document constitutes agreement by the recipient that no previously unpublished information contained herein will be published or disclosed without the prior written approval of Vascular Biogenics Limited with the exception that this document may be disclosed to study personnel under your supervision who need to know the contents for conducting the study and appropriate Institutional Review Boards (IRBs)ZEthics Committees (1EC) under the condition that the personnel have agreed to keep this information confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws, however, VBL shall be promptly notified of any such disclosure.

VBL Confidential Information	Page 88 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Attachment No. 4

List of SOPs applicable for the Study conduct

KCR SOP AND ASSOCIATED FORMS AND TEMPLATES

	Version	Effective date
101.1 MED. Feasibility process	5		06 Dec 11
Associated Forms And Templates: 101.1 MED. 01 Short Feasibility Worksheet	2		08 Mar 10
101.1 MED. 02 Feasibility Questionnaire	3		06 Dec 11
101.1 MED. 03 Feasibility Results	2		08 Mar 10
101.1 MED. 04 Thank You Letter	1		06 Dec 11
102.1 MED. Regulatory Submission for Clinical Study Application	4		13 Dec 12
102.3 MED. Updating Clinical Study Documentation	2		13 Aug 12
102.5 MED. Management of Regulatory Process	2		13 Aug 12
103.1 MED. Pre-Study Visit	2		21 Feb 11
Associated Forms And Templates:
103.1 MED. 01 Confirmation Pre-study Letter	2		21 Feb 11
103.1 MED. 02 Pre-study Visit Checklist	2		21 Feb 11
103.1 MED. 03 Pre-study Visit Report	2		21 Feb 11
103.1 MED. 04 Follow-up Pre-study Visit Letter	2		21 Feb 11
103.1 MED. 05 Site Selection Summary	2		21 Feb 11
103.1 MED. 06 Site Selection letter	2		21 Feb 11
103.1 MED. 07 Site Exclusion Letter	2		21 Feb 11
103.1 MED. 08 Declaration on Facilities 103.1 MED. 09 Curriculum Vitae form 103.1 MED. 10 Contact Data Form 103.1 MED. 11 Pre-study Visit Agenda	2 3 2 1		21 Feb 11 21 Jun 11 21 Feb 11 21 Feb 11
104.1 MED. Informed Consent Form	3		10 Nov 11
Associated Forms And Templates:
104.1 MED. 01 Informed Consent Form Approval Process	2		10 Nov 11
104.1 MED. 02 Informed Consent Form Checklist	2		10 Nov 11
104.1 MED. 03 Patient Information and Informed Consent Form Version Log	2		10 Nov 11
104.1 MED. 04 Informed Consent Form local adjustment	3		10 Nov 11

VBL Confidential Information	Page 89 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

105.1 MED. Initiation Visit	2	04 Mar 11
Associated Forms And Templates:
105.1 MED. 01 Confirmation Initiation Visit Letter	2	04 Mar 11
105.1 MED. 02 Site Initiation Visit Checklist	2	04 Mar 11
105.1 MED. 03 IMP Release Form	2	04 Mar 11
105.1 MED. 04 Site Green Light Approval	2	04 Mar 11
105.1 MED. 05 Site Initiation Visit Report	2	04 Mar 11
105.1 MED. 06 Delegation of Responsibilities Log	2	04 Mar 11
105.1 MED. 07 Site Visit Log	2	04 Mar 11
105.1 MED. 08 Subject Identification Log	3	04 Mar 11
105.1 MED. 09 Subject Screening and Randomization Log	3	04 Mar 11
105.1 MED. 10 Follow-up Site Initiation Visit Letter	2	04 Mar 11
105.1 MED. 11 Financial Disclosure Form	2	04 Mar 11
105.1 MED. 12 Subject pre-screening Log	2	04 Mar 11
105.1 MED. 13 Site Initiation Visit Agenda	2	22 Jan 13
105.1 MED. 14 List of Site Initiation Visit Activities	1	04 Mar 11
105.1 MED. 15 Consent to Processing Personal Data	1	02 Jun 11
105.1 MED. 16 Instruction on How to Manage Consent for Personal Data in Clinical Operation Department	1	27 Aug 12
106.1 MED. Monitoring Visit	2	18 Apr 11
Associated Forms And Templates:
106.1 MED. 01 Confirmation Monitoring Visit Letter	2	18 Apr 11
106.1 MED. 02 Monitoring Visit Report	3	18 Apr 11
106.1 MED. 03 Contact Report	2	18 Apr 11
106.1 MED. 04 Subject Visit Status	2	18 Apr 11
106.1 MED. 05 Note to File	3	18 Apr 11
106.1 MED. 06 Follow-up Monitoring Visit Letter	2	18 Apr 11
106.1 MED. 07 Monitoring Visit and Reporting Plan	2	18 Apr 11
106.1 MED. 08 Data Clarification Form 106.1 MED. 09 Site Personal Training Log 106.1 MED. 10 Confidentiality Violation Log	1 1 1	18 Jul 11 26 Jun 12 26 Jun 12
106.2 MED. Taking Over The Study	3	31 May 13
Associated Forms And Templates:
106.2 MED. 01 CRA Site Take-Over Checklist	5	31 May 13
106.2 MED. 02 CTA Take-Over Checklist	2	31 May 13
106.3 MED. Co-Monitoring Visit	2	25 Jul 11
106.3 MED. 02 Co-monitoring Visit Report: Quality Control Assessment	2	25 Jul 11
106.4 MED. Reporting Protocol Deviations	2	10 Aug 10
Associated Forms And Templates:
106.4 MED. 01 Protocol deviation report 106.4 MED. 02 Protocol Deviation Cumulative List	2 1	10 Aug 10 10 Aug 10
107.1 MED. Close-out Visit	3	29 Dec 11

VBL Confidential Information	Page 90 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Associated Forms And Templates:
107.1 MED. 01 Confirmation Close-out Visit Letter	2	30 Apr 11
107.1 MED. 02 Close out Visits Plan	2	30 Apr 11
107.1 MED. 03 Close out Visit Checklist	2	30 Apr 11
107.1 MED. 04 Close out Visit Report	2	30 Apr 11
107.1 MED. 05 Record Retention Form	2	30 Apr 11
107.1 MED. 06 Site Close out Assessment	2	30 Apr 11
107.1 MED. 07 Follow-up Close out Visit Letter	2	30 Apr 11
108.1 MED. Translation Associated Forms And Templates: 108.1 MED. 01 Translation Certificate	3 3	19 Sep 11 19 Sep 11
109.1 MED. Clinial Trial Documents	4	16 Sep 13
Associated Forms And Templates:
109.1 MED 01 Essential Documents	4	16 Sep 13
109.3 MED. Trial Master File	1	16 Sep 13
Associated Forms And Templates:
109.2 MED. 01 Trial Maser File Table of Content	1	16 Sep 13
109.2 MED. 02 Trial Maser File and Shadow File Review Form 109.2 MED. 03 TMF Transfer Form 109 3 MED 04 Study Documentation Management Form	1 1 1	16 Sep 13 16 Sep 13 16 Sep 13
109.5 MED. Investigator’s File	1	16 Sep 13
Associated Forms And Templates:
109.5 MED. 01 Investigator’s File Table of Content	1	16 Sep 13
109.5 MED. Electronic Study Folder and Shadow File 109.7 MED.01 Shadow File Coordinators Log 109.7 MED.02 Electronic Folder Names 109.7 MED.03 Example of Electronic Study Folder and Shadow File Structure	1 1 1 1	16 Sep 13 16 Sep 13 16 Sep 13 16 Sep 13
110.1 MED. Clinical Supplies	3	16 Sep 13
Associated Forms And Templates:
110.1 MED. 01 Temperature Log	3	16 Sep 13
110.1 MED. 02 Clinical Supply Shipment Management Log	3	16 Sep 13
110.1 MED. 03 Clinical Supply Accountability Form	3	16 Sep 13
110.1 MED. 04 Re-labelling Report	3	16 Sep 13
110.1 MED. 05 Investigational product RECALL form	3	16 Sep 13
110.1 MED. 06 Investigational product RETURN form	3	16 Sep 13
110.1 MED. 07 Clinical Supply Destruction Report 110.1 MED.08 Site Investigational Product Accountability Log	3 1	16 Sep 13 16 Sep 13
111.1 MED. Clinical Trial Materials	2	30 Sep 13
Associated Forms And Templates:
111.1 MED.01 Trial Supply Shipment Form	4	30 Sep 13
111.1 MED.02 Controlled Copy Distribution Log	3	30 Sep 13
111.1 MED.03 Frozen Samples storage log	3	30 Sep 13
111.1 MED.04 Investigator’s Brochure Acknowledgement of Receipt	2	30 Sep 13

VBL Confidential Information	Page 91 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

112.1 MED. Serious Adverse Event Reporting	3	08 Mar 13
Associated Forms And Templates:
112.1 MED. 01 SAE Pregnancy Report Form	3	08 Mar 13
112.2 MED. Distribution of SUSAR reports	2	15 Sep 11
Associated Forms And Templates:
112.2 MED. 01 SUSAR Reports Tracking Log	2	15 Sep 11
112.5 MED. Safety Management Principles	1	16 Sep 2013
114.1 MED. Insurance in Clinical Trial Associated Forms And Templates: 114.1 MED. 01 Questionnaire for Insurance Purposes	3 3	15 Apr 13 15 Apr 13
116.1 MED. Clinical Study Report	3	28 Jun 13
Associated Forms And Templates:
116.1MED. 01 Clinical Study Report Tracking Log	3	28 Jun 13
117.1 MED. Archiving Study Files	3	09 Sep 13
Associated Forms And Templates:
117.1 MED. 01 Archiving Facility Log	3	09 Sep 13
117.1 MED. 02 Archiving Coordinator Log	2	09 Sep 13
117.1 MED. 03 Archiving Coordinator Backup Log	2	09 Sep 13
117.1 MED. 04 Archiving Coordinator Take Over	2	09 Sep 13
117.1 MED. 05 Post Study Checklist	3	09 Sep 13
117.1 MED. 06 Content of Archived Box	2	09 Sep 13
117.1 MED. 07 List of Archived Studies	2	09 Sep 13
117.1 MED. 08 Retrieve from Archives Request	2	09 Sep 13
117.1 MED. 09 Confirmation of Destruction	2	09 Sep 13
117.1 MED. 10 Inventory of Archiving Boxes	2	09 Sep 13
117.1 MED. 11 Inventory of Archiving Locking Seals	2	09 Sep 13
117.1 MED. 12 Content of Archiving File	2	09 Sep 13
117.3 MED Management of Electronic Correspondence	1	29 Mar 13
121.1 MED. Contracts with Investigators and Investigational Sites	4	01 Feb 10
Associated Forms And Templates: 121.1 MED. 01 Bilateral contract (investigator) 121.1 MED. 02 Bilateral contract (centre)	4 4	08 Aug 11 08 Aug 11
121.1 MED. 03 Tripartite contract (investigator & centre) 121.1 MED. 04 Bilateral contract (investigator-coordinator) 121.1 MED. 06 Lend agreement (investigator) 121.1 MED. 07 Lend agreement (centre) 121.1 MED. 08 Service agreement (contractor with team)	4 4 2 2 2	08 Aug 11 08 Aug 11 08 Aug 11 08 Aug 11 08 Aug 11
121.1 MED. 09 Service agreement (single contractor) 121.1 MED. 10 Bilateral contract (investigator) – MD 121.1 MED. 11 Bilateral contract (centre) – MD	2 2 2	08 Aug 11 08 Aug 11 08 Aug 11
121.1 MED. 12Tripartite contract (investigator & centre) – MD	2	08 Aug 11

VBL Confidential Information	Page 92 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

121.1 MED. 13 Bilateral contract (investigator-coordinator) – MD	2	08 Aug 11
122.1 MED. Confidentiality Agreements and Confidentiality Obligation	3	14 Mar 11
Associated Forms And Templates: 122.1 MED. 01 CA general unilateral (investigator—centre) 122.1 MED. 02 CA study specific unilateral (investigator—centre) 122.1 MED. 03 CA general unilateral (sponsor—contractor—other) 122.1 MED. 04 CA study specific unilateral (sponsor—contractor—other) 122.1 MED. 05 CA general mutual (sponsor—contractor—other) 122.1 MED. 06 CO in feasibility only (investigator) 122.1 MED. 07 CA/CO explanatory notice	2 2 2 2 2 3 2	15 Feb 11 15 Feb 11 15 Feb 11 15 Feb 11 15 Feb 11 15 Feb 11 01 Mar 11
123.1 MED. Principles of drawing contracts and master service agreements	2	28 Mar 11
Associated Forms And Templates: 123.1 MED. 01 KCR Group Contract Template:         Master Service Agreement 123.1 MED. 02 KCR Group Contract Template:         Service Agreement for a clinical study conduct	2 1	28 Mar 11 20 Oct 08
124.1 MED. Fraud and Misconduct	3	11 Feb 13
125.1 MED. Purchases Within a Project	1	25 Jul 11
127.1 MED. Legislation in Clinical Trials	2	31 Jul 13
127.3 MED Regulatory Intelligence Associated Forms And Templates: 127.3 MED.01 Regulatory Intelligence Responsibilities	1 1	28 Dec 12 28 Dec 12
128.1 MED. Communication with Subcontractor Associated Forms And Templates: 128.1 MED. 01 Subcontractor Tracking Log	1 1	01 Sep 11 01 Sep 11
129.1 MED. Annual Progress Report to Competent Authorities	2	30 Sep 11
Associated Forms And Templates:
129.1 MED. 01 Annual Progress Report Template	2	30 Sep 11
130.1 MED. Preparing Monitoring Plan	1	25 Nov 11
Associated Forms And Templates:
130.1 MED. 01 Monitoring Plan	1	25 Nov 11
131.1 MED. Communication Plan Associated Forms And Templates:	1	30 Apr 12
131.1 MED. 01 Communication GLOBAL Contact List	1	30 Apr 12
131.1 MED. 02 Communication COUNTRY Contact List	1	30 Apr 12
131.1 MED. 03 Communication VENDOR Contact List	1	30 Apr 12
131.1 MED. 04 Study Team Delegation Log	1	30 Apr 12

VBL Confidential Information	Page 93 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

131.1 MED 05 Communication Plan	1	30 Apr 12
132.1 MED. Unbliding	1	28 Aug 12
Associated Forms And Templates:
132.1 MED. 01 Unblinding Contact List	1	28 Aug 12
132.1 MED. 02 Unblinding Report	1	28 Aug 12
132.2 MED. 03 Unblinding Listing	1	28 Aug 12
134.1.MED Principal Investigator Change	1	04 Apr 13
Associated Forms And Templates:
134 1 MED 01 Principal Investigator Change Checklist 131.1. MED. 03 134 1 MED 02 Letter to Competent Authorities About Principal Investigator Change	1 1	04 Apr 13 04 Apr 13

VBL Confidential Information	Page 94 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Attachment No. 5

List of third parties engaged by the Sponsor for the conduct of the Study

a. Legal representative (SCIderm GmbH): CRO shall undertake the following obligation, and shall indemnify the sponsor for any damage in case it will breach such obligation: notify immediately SCIderm GmbH and the Sponsor of any untoward occurrences, including serious breaches of the protocol, GCP or regulations, occurring in the clinical trial.

b. Data Management: CRO shall act according to the procedures, as shall be determined for this clinical trial.

VBL Confidential Information	Page 95 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

Attachment No. 6

Study Budget

Specification of anticipated costs and expenses

Ref. #	Service	Job position		Unit Cost (€)		Quantity of hours units		Total		KCR Notes / Comments
A	MEDICAL WRITING								[***]	[***]
B	STUDY FAMILIARIZATION & TRAINING								[***]
B.1	Kick-off Meeting—attendance		[***]		[***]		[***]		[***]	[***]
B.3	Monitors training (therapeutic)		[***]		[***]		[***]		[***]	[***]
B.4	Monitors training (therapeutic)		[***]		[***]		[***]		[***]	[***]
B.5	Investigator’s meeting—attendance and travel		[***]		[***]		[***]		[***]	[***]
B.6	Investigator’s meeting—attendance and travel		[***]		[***]		[***]		[***]	[***]
B.11	Investigator’s meeting—attendance and travel		[***]		[***]		[***]		[***]	[***]
B.12	Investigator’s meeting—prepare presentation		[***]		[***]		[***]		[***]	[***]
B.13	Investigator’s meeting organization		[***]		[***]		[***]		[***]	[***]
B.14	Familiarization with study documentation, SOPs and study specifics		[***]		[***]		[***]		[***]	[***]
C	SITE MANAGEMENT IN HOUSE (including site payments)								[***]
C.1	Site contacts over phone and written communication		[***]		[***]		[***]		[***]	[***]
C.2	CRF off site management		[***]		[***]		[***]		[***]	[***]
C.3	Resolve issues & queries		[***]		[***]		[***]		[***]	[***]
C.4	Administer investigators grants		[***]		[***]		[***]		[***]	[***]

VBL Confidential Information	Page 96 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

						[***]
C.5	Collect Pre-Study/Regulatory Documentation from sites and Sponsor	[***]	[***]	[***]	[***]	[***]
D	STUDY ADMINISTRATION & DOCUMENT MANAGEMENT				[***]
D.1	Set up study Trial Master Files	[***]	[***]	[***]	[***]	[***]
D.2	Create Investigator Binders	[***]	[***]	[***]	[***]	[***]
D.3	Maintain & update study Trial Master Files and project specific files	[***]	[***]	[***]	[***]	[***]
D.4	Archive, retain or return Study Documentation	[***]	[***]	[***]	[***]	[***]
E	STUDY AUTHORIZATION & CONTRACTS				[***]
E.1	Develop local Informed Consent Form	[***]	[***]	[***]	[***]	[***]
E.2	Develop local Informed Consent Form	[***]	[***]	[***]	[***]	[***]
E.3	Coordinate translation/preparation process (protocol synopsis, drug labels, back translation)	[***]	[***]	[***]	[***]	[***]
E.4	Translation and country adaptation of drug labels	[***]	[***]	[***]	[***]	[***]
E.5	Development of project specific contract template	[***]	[***]	[***]	[***]	[***]
E.6	Preparing countries specific contract templates from the project specific template	[***]	[***]	[***]	[***]	[***]
E.7	Negotiate Investigator Budget & CSA (+ 2nd for hospital authorities)	[***]	[***]	[***]	[***]	[***]
E.8	Negotiate Investigator Budget & CSA (+ 2nd for hospital authorities)	[***]	[***]	[***]	[***]	[***]
E.9	Development of Authorization Letters	[***]	[***]	[***]	[***]	[***]
E.10	Initial submission to CA and EC	[***]	[***]	[***]	[***]	[***]

VBL Confidential Information	Page 97 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

E.11	Initial submission to CA and EC	[***]	[***]	[***]	[***]	[***]
E.12	Regulatory maintenance—administrative amendments	[***]	[***]	[***]	[***]	[***]
E.13	Regulatory maintenance—substantial amendments	[***]	[***]	[***]	[***]	[***]
E.14	Project Management—Regulatory Affairs	[***]	[***]	[***]	[***]	[***]
E.15	Regulatory Manager—Teleconferences	[***]	[***]	[***]	[***]	[***]
E.16	Insurance arrangement	[***]	[***]	[***]	[***]	[***]
F	SITE SELECTION ACTIVITIES				[***]
F.1	Identify Investigative Sites	[***]	[***]	[***]	[***]	[***]
F.2	Site Selection Visits—visits	[***]	[***]	[***]	[***]	[***]
F.3	Site Selection Visits—travelling	[***]	[***]	[***]	[***]	[***]
G	MONITORING				[***]
G.1	Site Initiation Visits—visits	[***]	[***]	[***]	[***]	[***]
G.2	Site Initiation Visits—travelling	[***]	[***]	[***]	[***]	[***]
G.3	Interim Monitoring Visits—visits	[***]	[***]	[***]	[***]	[***]
G.4	Interim Monitoring Visits—travelling	[***]	[***]	[***]	[***]	[***]
G.5	Site Close-out Visits—visits	[***]	[***]	[***]	[***]	[***]
G.6	Site Close-out Visits—travelling	[***]	[***]	[***]	[***]	[***]
H	MEDICAL MONITORING				[***]	[***]
I	SAFETY REPORTING				[***]	[***]
J	DATA MANAGEMENT				[***]	[***]
K	PROJECT MANAGEMENT				[***]
K.1	Project management	[***]	[***]	[***]	[***]	[***]

VBL Confidential Information	Page 98 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

									[***]
K.3	Internal team meetings—COPM participation	[***]		[***]		[***]		[***]	[***]
K.5	Internal team meetings—CRAs participation	[***]		[***]		[***]		[***]	[***]
K.6	Verification of monitoring reports	[***]		[***]		[***]		[***]	[***]
L	QUALITY ASSURANCE SERVICES							[***]
L.1	Quality assurance services—Clinical management	[***]		[***]		[***]		[***]	[***]
CRO TOTAL						[***]		[***]
	ESTIMATED PASS THROUGH COSTS (this is rough estimation of the majority costs which should be taken into account and not directly paid by Sponsor)		Unit Cost (€)		Quantity of units		Total
1	Regulatory costs							[***]
1.1	Ethics Committee fees + RA fee					[***]		[***]	[***]
1.2	Custom clearance							[***]	[***]
1.3	Insurance							[***]	[***]
2	Travel costs							[***]

VBL Confidential Information	Page 99 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

2.1	CRA Travel (hotels, tickets, allowances)		[***]		[***]		[***]	[***]
2.2	QAD Travel (hotels, tickets, allowances)		[***]		[***]		[***]	[***]
2.3	Investigator Meetings travel and hotel costs (per attendee)		[***]		[***]		[***]	[***]
2.4	Patients travel costs		[***]		[***]		[***]	[***]
3	Administration						[***]
3.1	Copies / duplication (binding and photocopies included)		[***]		[***]		[***]	[***]
3.2	Courier / shipment		[***]		[***]		[***]	[***]
3.3	Telephone / fax		[***]		[***]		[***]	[***]
4	Translation						[***]
4.1	Translation of study documents		[***]		[***]		[***]	[***]
5.	Other costs						[***]
5.1	Overnight stay						[***]	[***]
PASS-THROUGH COSTS TOTAL							[***]
	SERVICE PROVIDERS COSTS	Unit Cost (€)		Quantity of units		Total
1	Central Laboratory						[***]
2	Data Management						[***]
3	Drug Supply						[***]
4	IVRS						[***]
5	Statistical Analysis and CSR						[***]
SERVICE PROVIDORS COSTS TOTAL							[***]

VBL Confidential Information	Page 100 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	INVESTIGATORS FEES	Unit Cost (€)		Quantity of units		Total
1							[***]
1.1	Investigators fee		[***]		[***]		[***]	[***]
1.2	Country study co-ordinator fees		[***]		[***]		[***]	[***]
1.3	Investigators fee (screen failures)		[***]		[***]		[***]	[***]
1.4	Start-up fees (Polish sites)		[***]		[***]		[***]	[***]
1.5	Archiving fees (Polish sites)		[***]		[***]		[***]	[***]
INVESTIGATORS FEES TOTAL							[***]
TOTAL CRO FEES								[***]
TOTAL PASS THROUGH COSTS								[***]
TOTAL VENDORS COSTS								[***]
TOTAL INVESTIGATORS FEES								[***]
PROJECT GRAND TOTAL								[***]

VBL Confidential Information	Page 101 of 101 Version 2.2 02 DEC 2013
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].